A5016244479- Angiogenesis and VEGF in Cancer
- Cell death mechanisms and regulation
- Gastroesophageal reflux and treatments
- NF-κB Signaling Pathways
- Endoplasmic Reticulum Stress and Disease
- Helicobacter pylori-related gastroenterology studies
- Autophagy in Disease and Therapy
- Protease and Inhibitor Mechanisms
- Liver physiology and pathology
- Peroxisome Proliferator-Activated Receptors
- Wound Healing and Treatments
- Cancer, Hypoxia, and Metabolism
- Gastrointestinal motility and disorders
- DNA Repair Mechanisms
- Organoselenium and organotellurium chemistry
- Ginseng Biological Effects and Applications
- Sphingolipid Metabolism and Signaling
- Estrogen and related hormone effects
- Hepatocellular Carcinoma Treatment and Prognosis
- Natural product bioactivities and synthesis
- Microtubule and mitosis dynamics
- Redox biology and oxidative stress
- Digital Imaging in Medicine
- Genomics, phytochemicals, and oxidative stress
- Reconstructive Facial Surgery Techniques
Hanmi Pharmaceutical (South Korea)
2018-2025
Yonsei University
2007-2024
Wonkwang University
2023
University of Ulsan
2023
Asan Medical Center
2023
Ulsan College
2023
Korea University Medical Center
2023
Seoul National University Bundang Hospital
2023
Inje University
2023
Kyungpook National University
2023
1,25-dihydroxyvitamin D3 (VD3), an active form of Vitamin D, is photosynthesized in the skin vertebrates response to solar ultraviolet B radiation (UV-B). VD3 deficiency can cause health problems such as immune disease,metabolic disease, and bone disorders. It has also been demonstrated that involved reproductive functions. Female sex hormones estrogen progesterone are biosynthesized mainly ovarian granulosa cells follicle develops. The functions include regulation estrus cycle puberty well...
Abstract Peroxisome proliferator-activated receptor gamma (PPARγ) is a well-known therapeutic target for type 2 diabetes as well potential effective anti-cancer drug, since PPARγ ligands such ciglitazone (Cig) frequently cause cell death in many types of cancer cells and suppress tumor growth. However, patients acquire chemo-resistance or radio-resistance after chemo radiotherapy, it still unclear. In the difficulty drugs, we developed novel agonist CB13 (1-benzyl-5-(4-methylphenyl) pyrido...
Hyun Lim, Ju Yup Lee, Yong Hwan Kwon, Hee Seok Moon, Jong Kyu Park, Ki Bae Kim, Sang Wook Young Hoon Youn, Gyun Gwang Ha Ji Won Jae-Young Jang, Kye Sook Joong Goo Hyun-Soo Su Jin Hong, Kwang Jae Suck Chei Choi, Jeong Seop Nayoung Jong-Jae Yirang Sung Hwoon-Yong Jung. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl240390
Abstract Peroxisome proliferator-activated receptor gamma (PPARɣ) agonists exert powerful anticancer effects by suppressing tumor growth. In this study, we developed PPZ023 (1-(2-(ethylthio)benzyl)-4-(2-methoxyphenyl)piperazine), a novel PPAR ligand candidate, and investigated the underlying signaling pathways in both non-small-cell lung cancer (NSCLC) radio-resistant NSCLC cells. To identify whether has radioresistant cells, performed WST-1, LDH, Western blot, caspase-3 -9 activity assays....
We experienced satisfactory outcomes by synchronously transplanting an artery and vein using anterolateral thigh flap pedicle between the vascular recipient vessel of a for scalp reconstruction. A 45-year-old man developed subdural hemorrhage due to fall injury. In this patient, right temporal cranium was missing patient had 4×3 cm 6×5 defects. planned reconstruction latissimus dorsi free flap. Intraoperatively, there severe injury superficial because previous neurosurgical operations. 15...
Background: Esomeprazole, a proton pump inhibitor (PPI), is widely used to treat acid-related disorders, but it has short plasma half-life which can cause insufficient gastric acid suppression, such as nocturnal breakthrough. A new dual delayed-release (DR) formulation of esomeprazole (Esomezol DR), was developed extend the duration suppression. Purpose: This study aimed evaluate pharmacokinetics (PKs) and pharmacodynamics (PDs) for DR compared conventional enteric-coated (EC) (Nexium) in...
Abstract Background Peroxisome proliferator-activated receptor γ (PPARγ) agonists frequently induce cell death in human non-small-cell lung cancer (NSCLC) cells. However, majority of NSCLC patients acquire resistance after therapy, and it is still unclear. Methods In this study we investigated the apoptotic mechanism anti-cancer effects a novel purine-based PPARγ agonist, CB11 (8-(2-aminophenyl)-3-butyl-1,6,7-trimethyl-1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione), on mediates PPARγ-dependent...
Hepatocyte growth factor (HGF) and its receptor, cMET, play critical roles in cell proliferation, angiogenesis invasion a wide variety of cancers. We therefore examined the anti-tumor activity humanized monoclonal anti-HGF antibody, YYB-101, nude mice bearing human glioblastoma xenografts as single agent or combination with temozolomide. HGF neutralization, The extracellular signal-related kinases 1 2 (ERK1/2) phosphorylation, HGF-induced scattering were assessed HGF-expressing lines treated...
Cancer is a complex disease with profound genomic alterations and extensive heterogeneity. Recent studies on large-scale genomics have shed light the impact of core oncogenic pathways, which are frequently dysregulated in wide spectrum cancer types. Aberrant activation hepatocyte growth factor (HGF) signaling axis has been associated promoting various programs during tumor initiation, progression, treatment resistance. As result, HGF-targeted therapy emerged as an attractive therapeutic...
A radioresistant cell line was established by fractionated ionizing radiation (IR) and assessed a clonogenic assay, flow cytometry, Western blot analysis, as well zymography wound healing assay. Microarray performed to profile global expression search for differentially expressed genes (DEGs) in response IR. H460R cells demonstrated increased scattering acidic vesicular organelles compared with parental cells. Concomitantly, showed characteristics of migration matrix metalloproteinase...
Background: YYB101, a humanized monoclonal antibody against hepatocyte growth factor (HGF), has shown safety and efficacy in vitro vivo. This is first-in-human trial of this antibody. Materials Methods: YYB101 was administered intravenously to refractory cancer patients once every 4 weeks for 1 month, then 2 until disease progression or intolerable toxicity, at doses 0.3, 1, 3, 5, 10, 20, 30 mg/kg, according 3+3 dose escalation design. Maximum tolerated dose, safety, pharmacokinetics,...